Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

In vivo genome editing for hemophilia B therapy by the combination of rebalancing and therapeutic gene knockin using a viral and non-viral vector
Jeong Hyeon Lee, Jeong Pil Han, Dong Woo Song, et al.
Molecular Therapy — Nucleic Acids (2023) Vol. 32, pp. 161-172
Open Access | Times Cited: 23

Showing 23 citing articles:

2025 Clinical Trials Update on Hemophilia, VWD, and Rare Inherited Bleeding Disorders
Debbie Jiang, Michael Wang, Allison P. Wheeler, et al.
American Journal of Hematology (2025)
Closed Access | Times Cited: 3
Delivery of nucleic acid based genome editing platforms via lipid nanoparticles: Clinical applications
Razan Masarwy, Lior Stotsky‐Oterin, Aviad Elisha, et al.
Advanced Drug Delivery Reviews (2024) Vol. 211, pp. 115359-115359
Closed Access | Times Cited: 16
Recent Therapeutic Gene Editing Applications to Genetic Disorders
Éric Deneault
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 5, pp. 4147-4185
Open Access | Times Cited: 12
Sleeping Beauty mRNA-LNP enables stable rAAV transgene expression in mouse and NHP hepatocytes and improves vector potency
Philip M. Zakas, Sharon C. Cunningham, Ann Doherty, et al.
Molecular Therapy (2024) Vol. 32, Iss. 10, pp. 3356-3371
Closed Access | Times Cited: 8
Gene Therapy Approaches for the Treatment of Hemophilia B
Anastasiia B. Soroka, Sofya G. Feoktistova, Olga Mityaeva, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10766-10766
Open Access | Times Cited: 15
In vivo LNP-CRISPR Approaches for the Treatment of Hemophilia
Jeong Hyeon Lee, Jeong Pil Han
Molecular Diagnosis & Therapy (2024) Vol. 28, Iss. 3, pp. 239-248
Open Access | Times Cited: 6
Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives
Nikita Chernyi, Darina Gavrilova, Mane Saruhanyan, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 854-854
Open Access | Times Cited: 5
Applications and Research Advances in the Delivery of CRISPR/Cas9 Systems for the Treatment of Inherited Diseases
Xinyue Lu, Miaomiao Zhang, Ge Li, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13202-13202
Open Access | Times Cited: 12
Could targeted gene insertion of factor 9 be a potential durable treatment for hemophilia B?
Giancarlo Castaman, Mirko Pinotti
Expert Review of Hematology (2025)
Closed Access
Engineering adeno-associated viral vectors for CRISPR/Cas based in vivo therapeutic genome editing
Buhle Moyo, Leo D. Brown, Ishika I Khondaker, et al.
Biomaterials (2025), pp. 123314-123314
Closed Access
Retina-directed gene therapy: Achievements and remaining challenges
Josef Biber, Catharina Gandor, Elvir Bećirović, et al.
Pharmacology & Therapeutics (2025), pp. 108862-108862
Closed Access
CRISPR Advancements for Human Health.
Daniel J. Davis, Sai Goutham Reddy Yeddula
PubMed (2024) Vol. 121, Iss. 2, pp. 170-176
Closed Access | Times Cited: 2
Gene editing in liver diseases
Laura Torella, Nerea Santana‐Gonzalez, Nerea Zabaleta, et al.
FEBS Letters (2024)
Open Access | Times Cited: 2
Treatment of congenital coagulopathies, from biologic to biotechnological drugs: The relevance of gene editing (CRISPR/Cas)
Juan A. De Pablo-Moreno, Andrea Miguel-Batuecas, E. Carlos Rodríguez‐Merchán, et al.
Thrombosis Research (2023) Vol. 231, pp. 99-111
Open Access | Times Cited: 6
CRISPR-Cas9 Direct Fusions for Improved Genome Editing via Enhanced Homologous Recombination
Tahmina Tabassum, Giovanni Pietrogrande, Michael D. Healy, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14701-14701
Open Access | Times Cited: 5
CRISPR-based precision medicine for hematologic disorders: Advancements, challenges, and prospects
Sounak Sahu, Maria Poplawska, Seah H. Lim, et al.
Life Sciences (2023) Vol. 333, pp. 122165-122165
Closed Access | Times Cited: 4
In vivo liver targeted genome editing as therapeutic approach: progresses and challenges
Chiara Simoni, Elena Barbon, Andrés F. Muro, et al.
Frontiers in Genome Editing (2024) Vol. 6
Open Access | Times Cited: 1
Efficient and Safe In Vivo Treatment of Primary Hyperoxaluria Type 1 via LNP-CRISPR/Cas9-mediated glycolate oxidase disruption
Yanhong Jiang, Shuanghong Chen, Shenlin Hsiao, et al.
Molecular Therapy (2024)
Closed Access | Times Cited: 1
Terapia Génica como Tratamiento para la Hemofilia
Jennifer Cedillo-Prado, Rosana Córdova-Serrano
593 Digital Publisher CEIT (2023) Vol. 8, Iss. 5, pp. 5-16
Open Access | Times Cited: 1
Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight
Zhenjie Zhang, Siqi Zhang, Hoi Ting Wong, et al.
BioDrugs (2024) Vol. 38, Iss. 3, pp. 369-385
Open Access


Clinical pharmacology and therapy (2024) Vol. 34, Iss. 2
Open Access
CRISPR/Cas9 Edition of the F9 Gene in Human Mesenchymal Stem Cells for Hemophilia B Therapy
Irving Jair Lara-Navarro, Luis Felipe Jave‐Suárez, Juan Antonio Marchal, et al.
Life (2024) Vol. 14, Iss. 12, pp. 1640-1640
Open Access
Lipid Nanoparticle-Mediated Delivery of CRISPR-Cas9 for Therapeutic Gene Correction
Johanna Walther
(2023)
Open Access
Page 1

Scroll to top